Raymond James Financial
IMNM icon

Raymond James Financial’s Immunome IMNM Stock Holding History

Raymond James Financial’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-96,374
Closed -$2.11M – 5485
2026
Q1 		$2.11M Buy
96,374
+49,805
+107% +$1.11M ﹤0.01% 3325
2025
Q4 		$1M Buy
46,569
+36,269
+352% +$637K ﹤0.01% 3773
2025
Q3 		$121K Buy
10,300
+6,459
+168% +$64.3K ﹤0.01% 4721
2025
Q2 		$35.7K Sell
3,841
-8,209
-68% -$67.3K ﹤0.01% 5315
2025
Q1 		$81.1K Sell
12,050
-13,767
-53% -$132K ﹤0.01% 4582
2024
Q4 		$274K Buy
+25,817
New +$312K ﹤0.01% 4236

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Raymond James Financial's IMNM Position: Q2 2026 in Review

Raymond James Financial sold out of Immunome (IMNM) in Q2 2026, closing a stake of 96,374 shares — an estimated $2.11M sold.

Raymond James Financial first reported a position in IMNM in Q4 2024 and held it in 6 quarters. The position peaked at $2.11M in Q1 2026. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Raymond James Financial reported no remaining Immunome position as of Q2 2026 after selling out during the quarter.
  • Raymond James Financial sold 96,374 Immunome shares in Q2 2026, an estimated $2.11M.
  • Raymond James Financial first reported a position in Immunome in Q4 2024 and held it in 6 quarters.
  • Raymond James Financial's Immunome position peaked at $2.11M in Q1 2026.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.